[go: up one dir, main page]

WO2009126003A3 - Nouveaux dérivés de pyridine à substitution pyrazole et benzoxazole ou leurs sels pharmaceutiquement acceptables, leur procédé de préparation, et composition pharmaceutique contenant ces dérivés/sels en tant que principes actifs pour prévenir et traiter des troubles impliquant une prolifération cellulaire aberrante - Google Patents

Nouveaux dérivés de pyridine à substitution pyrazole et benzoxazole ou leurs sels pharmaceutiquement acceptables, leur procédé de préparation, et composition pharmaceutique contenant ces dérivés/sels en tant que principes actifs pour prévenir et traiter des troubles impliquant une prolifération cellulaire aberrante Download PDF

Info

Publication number
WO2009126003A3
WO2009126003A3 PCT/KR2009/001866 KR2009001866W WO2009126003A3 WO 2009126003 A3 WO2009126003 A3 WO 2009126003A3 KR 2009001866 W KR2009001866 W KR 2009001866W WO 2009126003 A3 WO2009126003 A3 WO 2009126003A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
cell proliferation
disorders involving
aberrant cell
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001866
Other languages
English (en)
Korean (ko)
Other versions
WO2009126003A2 (fr
WO2009126003A9 (fr
Inventor
고종성
이종국
조성윤
한선영
이정옥
류재욱
박경찬
한동초
하재두
박성규
정희정
권병목
유경호
심태보
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Chemical Technology KRICT
Korea Research Institute of Bioscience and Biotechnology KRIBB
Korea Institute of Science and Technology KIST
Original Assignee
Korea Research Institute of Chemical Technology KRICT
Korea Research Institute of Bioscience and Biotechnology KRIBB
Korea Institute of Science and Technology KIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Chemical Technology KRICT, Korea Research Institute of Bioscience and Biotechnology KRIBB, Korea Institute of Science and Technology KIST filed Critical Korea Research Institute of Chemical Technology KRICT
Publication of WO2009126003A2 publication Critical patent/WO2009126003A2/fr
Publication of WO2009126003A9 publication Critical patent/WO2009126003A9/fr
Publication of WO2009126003A3 publication Critical patent/WO2009126003A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés de pyridine à substitution pyrazole et benzoxazole ou leurs sels pharmaceutiquement acceptables, leur procédé de préparation, et une composition pharmaceutique contenant ces dérivés en tant que principes actifs pour prévenir et traiter des troubles impliquant une prolifération cellulaire aberrante. L'invention permet d'obtenir d'excellents effets pour inhiber une grande variété de protéines kinases, par exemple: c-Met, Ron, KDR, Lck, Flt1, Flt3, Tie2, TrkA, TrkB, b-Raf, Aurora-A et analogues, l'invention s'avère ainsi utile pour traiter des troubles impliquant une prolifération cellulaire aberrante, et peut être avantageusement utilisée pour prévenir et pour traiter des troubles impliquant une prolifération cellulaire aberrante.
PCT/KR2009/001866 2008-04-10 2009-04-10 Nouveaux dérivés de pyridine à substitution pyrazole et benzoxazole ou leurs sels pharmaceutiquement acceptables, leur procédé de préparation, et composition pharmaceutique contenant ces dérivés/sels en tant que principes actifs pour prévenir et traiter des troubles impliquant une prolifération cellulaire aberrante Ceased WO2009126003A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080033282A KR100979439B1 (ko) 2008-04-10 2008-04-10 신규 피라졸 및 벤즈옥사졸 치환된 피리딘 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물
KR10-2008-0033282 2008-04-10

Publications (3)

Publication Number Publication Date
WO2009126003A2 WO2009126003A2 (fr) 2009-10-15
WO2009126003A9 WO2009126003A9 (fr) 2009-12-10
WO2009126003A3 true WO2009126003A3 (fr) 2010-02-04

Family

ID=41162413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001866 Ceased WO2009126003A2 (fr) 2008-04-10 2009-04-10 Nouveaux dérivés de pyridine à substitution pyrazole et benzoxazole ou leurs sels pharmaceutiquement acceptables, leur procédé de préparation, et composition pharmaceutique contenant ces dérivés/sels en tant que principes actifs pour prévenir et traiter des troubles impliquant une prolifération cellulaire aberrante

Country Status (2)

Country Link
KR (1) KR100979439B1 (fr)
WO (1) WO2009126003A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
DE102009033208A1 (de) 2009-07-15 2011-01-20 Merck Patent Gmbh Aminopyridinderivate
KR101598664B1 (ko) 2013-09-04 2016-03-02 씨제이헬스케어 주식회사 피롤로피리다진 유도체를 포함하는 단백질 키나제 억제제
WO2018111049A1 (fr) * 2016-12-15 2018-06-21 한국생명공학연구원 Composition pharmaceutique destinée à prévenir ou à traiter des maladies associées à dyrk, comprenant un composé à base de pyridine comme principe actif
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
KR102200032B1 (ko) * 2019-03-13 2021-01-08 전남대학교산학협력단 호흡기 질환의 예방 또는 치료용 조성물
KR20220136542A (ko) 2021-03-30 2022-10-11 현대모비스 주식회사 차량 제어 시스템 및 방법
KR20220141124A (ko) 2021-04-12 2022-10-19 현대모비스 주식회사 차량 제어 시스템 및 방법
KR20220139065A (ko) 2021-04-07 2022-10-14 현대모비스 주식회사 차량 제어 시스템 및 방법
KR20220139492A (ko) 2021-04-07 2022-10-17 현대모비스 주식회사 차량 제어 시스템 및 방법
KR20220144544A (ko) 2021-04-20 2022-10-27 현대모비스 주식회사 차량 제어 시스템 및 방법
KR20220144545A (ko) 2021-04-20 2022-10-27 현대모비스 주식회사 차량 제어 시스템 및 방법
US12427985B2 (en) 2021-04-20 2025-09-30 Hyundai Mobis Co., Ltd. Vehicle control system and method
KR20250135111A (ko) * 2024-03-05 2025-09-12 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
US7348325B2 (en) * 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US7348325B2 (en) * 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KERI, G. ET AL.: "Signal Transduction Therapy with Rationally Designed Kinase Inhibitors", CURRENT SIGNAL TRANSDUCTION THERAPY, vol. 1, 2006, pages 67 - 95 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors

Also Published As

Publication number Publication date
KR100979439B1 (ko) 2010-09-02
KR20090107807A (ko) 2009-10-14
WO2009126003A2 (fr) 2009-10-15
WO2009126003A9 (fr) 2009-12-10

Similar Documents

Publication Publication Date Title
WO2009126003A3 (fr) Nouveaux dérivés de pyridine à substitution pyrazole et benzoxazole ou leurs sels pharmaceutiquement acceptables, leur procédé de préparation, et composition pharmaceutique contenant ces dérivés/sels en tant que principes actifs pour prévenir et traiter des troubles impliquant une prolifération cellulaire aberrante
WO2009139576A3 (fr) Dérivés de pyridine substitués avec de nouveaux benzoxazoles ou des sels pharmaceutiquement acceptables de ces composés, procédé de préparation de ces composés et compositions pharmaceutiques contenant ces composés comme principes actifs destinées à la prévention et au traitement d'une maladie à croissance cellulaire anormale
WO2009140128A3 (fr) Composés et compositions servant d'inhibiteurs de kinases
WO2009097287A9 (fr) Composés et compositions comme inhibiteurs de kinases
WO2010021918A8 (fr) Composés en tant qu'inhibiteurs de kinases
WO2008128038A3 (fr) Procédés et compositions permettant de traiter les dysfonctionnements cardiaques
WO2010011772A3 (fr) Inhibiteurs de la pyrazolopyridine kinase tricyclique
EP1973407A4 (fr) Composes spiro et procedes d utilisation
WO2007111904A3 (fr) Inhibiteurs de la c-met proteine kinase
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
MX2010008719A (es) Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina.
WO2007095223A3 (fr) PYRROLO(3,2-C) PYRIDINES utiles en tant qu'inhibiteurs de proteines-kinases
MY156822A (en) Indole derivatives as s1p1 receptor agonists
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
WO2007087283A3 (fr) Thiophene-carboxamides utiles en tant qu'inhibiteurs de proteines kinases
WO2009132774A8 (fr) Nouveaux dérivés substitués indolin-2-one et utilisation de ces derniers en tant qu'inhibiteurs de kinase activés par le mitogène p39
WO2007120760A3 (fr) Thiophène-carboxamides servant d'inhibiteurs de protéines kinases
NO20090171L (no) Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike
MX2009004771A (es) Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
WO2008060448A3 (fr) Inhibiteurs de la pak à petites molécules
WO2008020306A3 (fr) Dérivés d'isoindole
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2012001529A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09730861

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09730861

Country of ref document: EP

Kind code of ref document: A2